The Chief Commercial Officer (CCO) brings to Exela Pharma Sciences (Exela) exceptional commercial knowledge experience as well as an excellent track record of growth within a pharmaceutical company, specialty and/or branded generics. The CCO will serve as the key leader in refining and executing the company’s commercialization strategy and process, as well as growing its business in a complex, highly competitive and internationally evolving market. The CCO will be accountable for capitalizing on the strengths and opportunities of Exela, such as a strong drug delivery technology, quality processes, and solid financials. The CCO reports directly to the CEO of the Company and will provide the commercial leadership, intellectual impetus and strategic direction to both develop and execute the Company’s sales, marketing and commercial operations for the business. This is a P&L role with direct responsibility to achieve revenue and earnings objectives and maximize commercial potential. The CCO will be responsible driving commercialization strategies, as well as providing input to the internal R&D programs and leading the business development efforts.

GRAYKEY, LLC is a Consulting firm specializing in the pharmaceutical environment and related fields. I founded the company to bring my 27+ years of Brand, Generic and OTC pharmaceutical sales, marketing and management experience to organizations looking to understand this very dynamic and complex marketplace. Through my years of experience in the pharmaceutical business, I am able to bring a unique perspective on the challenges surrounding the marketing of brand, generic and OTC pharmaceuticals. I utilize my network of contacts throughout the globe to provide expert opinions on the various business strategies and tactics associated with a successful pharma venture. I can provide a global perspective having worked for two Indian pharma companies and traveled to India 49 times in 8 years. Understanding the cultural differences and having the ability to navigate these differences to gain a successful outcome is what GRAYKEY, LLC is all about.Through GRAYKEY, LLC I have served as an expert witness in litigation involving the pharmaceutical industry by offering a broad knowledge of pricing strategies, ANDA pharmaceutical product selection and development, sales and marketing tactics and the patent challenge landscape. Since October, 2011, I have successfully guided The Ritedose Corporation (owned by Private Equity firm Olympus Partners) through the set up and launch of their direct to market subsidiary Ritedose Pharmaceuticals, LLC. The Ritedose Corporation has been the worlds leading contract manufacturing organization since 1998 specializing in the manufacturing of unit dose nebulizers, ear drops, eye drops and liquid spoons. In 2011, TRC made a decision to enter the market directly to sell its nebulizer solutions. GRAYKEY, LLC was enlisted to assist them in the strategic analysis of their approach to market, as well as to manage the complete set up of their commercial operations. GRAYKEY, LLC continues to support new product launches for Ritedose.

As Sr. VP/GM, I will have full P&L responsibility for Patheon's newly acquired business, Banner Life Sciences (formerly Banner Pharmacaps), which will include the RX, OTC and Nutritional product lines utilizing Banner's proprietary soft gel technology platforms. Delivered high EBITDA performance on introduction of three generic Rx soft gel products capturing leading market shares (29%) on two of the three products. Created $15mn in revenue with limited pipeline to market directly.

President of KV's generic subsidiary, Nesher Pharmaceuticals. Relaunched Generic subsidiary in November 2010. Gained 40% Market Share on key product with annual revenue approximately $40mn. Led the Strategic Initiative to sell the generic subsidiary to a strategic partner or financial party.Completed $60mn sale transaction in August 2011 to Zydus Pharmaceuticals. Successfully managed all areas of product reintroduction, development activities and marketing promotions while operating under FDA consent decree. Full P&L responsibility.

President North America, Wockhardt, USA responsible for all aspects of Wockhardts efforts in North America including Morton Grove pharmaceuticals. Established process improvements that quickly improved service levels and supply chain effectiveness in a global network. Stabilized Wockhardt USA as a reputable, go to generic company. Improved cost efficiency of total US business, including Morton Grove Pharmaceuticals. Improved USA businesses into a positive EBITDA organization. Garnered significant market shares on 3 new product launches. Guided Brand business through significant sales growth in 2010 vs 2009. Established a team mentality within Wockhardt USA with an open door policy to Senior Leadership.

Working as an independent consultant for pharmaceutical firms desiring knowledge on the establishment of generic or specialty pharma companies in the US. Particular expertise in managing global businesses who desire to have a footprint in North America. Open to new start up ventures or assisting existing player to go to the next step in their evolution.

Launched Dr. Reddy’s direct generic presence in North America via establishment of complete front end commercial order to cash operations, including Sales, Marketing, Supply Chain, Customer Service, Warehouse & Distribution. Led strategic direction for business development, legal and product selection. Member of Dr. Reddy’s Management Council. Responsible for guiding 12 direct reports, 45 employees in Charlotte, 8 in NJ and 120 employees in US manufacturing operations. Recruited and led a top tier team that grew Dr. Reddy’s generic business from zero to over $540 M in 4 years into the 7th largest generic company in the US.Previously at Watson Laboratories as VP Sales/Mktg. Grew generic business from $100Mn to over $700Mn in 5 years. Integrated 3 mergers into Watson.

Built Sales & Marketing teams of Watson's Generic division. Full P&L responsibility, including involvement in product selection, BD strategy and M&A activities. Officer of the company and on the Executive Committee. Grew the division from 26 products ($120 M in sales) and #11 ranking in US Generic marketplace to over 150 products ($700 M in sales) and #2 ranking in 5 years. • Integrated 4 company acquisitions: Oclassen (dermatology specialty company), Royce Laboratories, Rugby Laboratories, and Schein Pharmaceuticals (generic companies). Developed combined company strategies and trade relations activities, label conversions and product rationalizations. Attracted and retained top talent, many of whom are still with Waston today. Left to pursue start up operations at Dr. Reddy's.

Directed overall marketing efforts of $120 M liquid and topical generic prescription drug line. Established marketing, pricing and contracting policies for prescription drug line. Responsible for the name change and integration of Barre-National into Alpharma in 1996.

Began pharmaceutical career carrying a bag and detailing physicians. Won Rookie of the Year as Field rep. Promoted to Hospital rep, then Clinical Conference Manager, then District Sales Manager, then Product Manager in Marketing on Brand side before moving over the Lederle Standard Products (generics) marketing prior to sale of American Cyanamid.